$WGS
GeneDx Holdings Corp. Stock $wgs

$wgs Overview Financials Valuation SEC Filings Company Website

2021 Q4 Form 10-K Financial Statement

#000181833122000037 Filed on March 14, 2022

Income Statement

Concept	2021 Q4	2021 Q3	2021 Q2
Revenue	$57.80M	$43.18M	$47.02M
YoY Change	-9.63%	11.84%	56.19%
Cost Of Revenue	$60.61M	$51.49M	$48.18M
YoY Change	-12.96%	51.33%	39.63%
Gross Profit	-$2.806M	-$8.309M	-$1.164M
YoY Change	-50.55%	-281.18%	-73.56%
Gross Profit Margin	-4.85%	-19.24%	-2.48%
Selling, General & Admin	$88.60M	$61.28M	$31.44M
YoY Change	4.17%	54.8%	71.95%
% of Gross Profit
Research & Development	$22.25M	$17.83M	$11.95M
YoY Change	-28.61%	-6.56%	27.68%
% of Gross Profit
Depreciation & Amortization	$5.795M	$5.491M	$5.619M
YoY Change	61.56%	79.03%	109.66%
% of Gross Profit
Operating Expenses	$110.8M	$79.11M	$43.40M
YoY Change	-4.62%	34.84%	56.96%
Operating Profit	-$115.8M	-$88.26M	-$45.45M
YoY Change	-7.41%	57.57%	33.04%
Interest Expense	$75.55M	$683.0K	$722.0K
YoY Change	-12383.74%	7.22%	-233.7%
% of Operating Profit
Other Income/Expense, Net	$75.60M	$121.0M	-$713.0K
YoY Change	-11948.75%	-20265.83%	-133.79%
Pretax Income	-$40.43M	$31.39M	-$46.16M
YoY Change	-67.83%	-155.45%	44.03%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$40.19M	$32.73M	-$46.16M
YoY Change	-68.03%	-157.81%	44.02%
Net Earnings / Revenue	-69.52%	75.8%	-98.18%
Basic Earnings Per Share		$0.17	-$41.94
Diluted Earnings Per Share	-$157.9K	$0.15	-$41.94
COMMON SHARES
Basic Shares Outstanding	241.3M shares	185.7M shares	1.101M shares
Diluted Shares Outstanding		210.3M shares	1.101M shares

Balance Sheet

Concept	2021 Q4	2021 Q3	2021 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$400.6M	$461.3M	$26.50M
YoY Change	36492.34%	40363.52%
Cash & Equivalents	$400.6M	$461.3M	$26.50M
Short-Term Investments
Other Short-Term Assets	$3.802M	$4.186M	$18.38M
YoY Change	-7.81%	1186.26%
Inventory	$33.46M	$31.17M	$29.13M
Prepaid Expenses	$19.15M	$24.39M	$18.38M
Receivables	$26.51M	$21.26M	$24.57M
Other Receivables	$54.00K	$413.0K	$437.0K
Total Short-Term Assets	$483.5M	$538.5M	$99.01M
YoY Change	177.73%	36647.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$62.72M	$60.33M	$62.10M
YoY Change	-0.62%
Goodwill	$0.00
YoY Change
Intangibles	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$6.930M	$3.613M	$3.596M
YoY Change	92.71%	-99.18%
Total Long-Term Assets	$70.55M	$64.85M	$76.52M
YoY Change	-9.01%	-85.35%
TOTAL ASSETS
Total Short-Term Assets	$483.5M	$538.5M	$99.01M
Total Long-Term Assets	$70.55M	$64.85M	$76.52M
Total Assets	$554.1M	$603.4M	$175.5M
YoY Change	120.19%	35.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$44.69M	$43.32M	$45.23M
YoY Change	67.16%
Accrued Expenses	$19.76M
YoY Change	66.68%
Deferred Revenue	$500.0K	$493.0K	$1.341M
YoY Change	-72.22%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$923.0K
YoY Change	-100.0%
Total Short-Term Liabilities	$101.3M	$71.61M	$72.61M
YoY Change	37.91%	161361.1%
LONG-TERM LIABILITIES
Long-Term Debt	$11.00M	$11.00M	$18.03M
YoY Change	-42.02%
Other Long-Term Liabilities	$21.91M	$21.70M	$21.91M
YoY Change	956.27%	40.03%
Total Long-Term Liabilities	$32.91M	$32.70M	$39.94M
YoY Change	56.36%	111.01%
TOTAL LIABILITIES
Total Short-Term Liabilities	$101.3M	$71.61M	$72.61M
Total Long-Term Liabilities	$32.91M	$32.70M	$39.94M
Total Liabilities	$166.0M	$212.3M	$407.6M
YoY Change	-32.87%	1266.33%
SHAREHOLDERS EQUITY
Retained Earnings	-$575.4M	-$535.3M	-$568.0M
YoY Change	74.35%
Common Stock	$24.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$388.1M	$391.0M	-$566.5M
YoY Change
Total Liabilities & Shareholders Equity	$554.1M	$603.4M	$175.5M
YoY Change	120.19%	35.82%

Cashflow Statement

Concept	2021 Q4	2021 Q3	2021 Q2
OPERATING ACTIVITIES
Net Income	-$40.19M	$32.73M	-$46.16M
YoY Change	-68.03%	-157.81%	44.02%
Depreciation, Depletion And Amortization	$5.795M	$5.491M	$5.619M
YoY Change	61.56%	79.03%	109.66%
Cash From Operating Activities	-$51.98M	-$70.94M	-$25.30M
YoY Change	183.56%	-5.15%	7.34%
INVESTING ACTIVITIES
Capital Expenditures	-$7.693M	-$3.618M	-$4.481M
YoY Change	-33.1%	-82.33%	-144.06%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$7.693M	-$3.618M	-$4.481M
YoY Change	-33.1%	-82.33%	-55.94%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-1.029M	499.4M	-2.369M
YoY Change	-111.29%	316.37%	141.73%
NET CHANGE
Cash From Operating Activities	-51.98M	-70.94M	-25.30M
Cash From Investing Activities	-7.693M	-3.618M	-4.481M
Cash From Financing Activities	-1.029M	499.4M	-2.369M
Net Change In Cash	-60.71M	424.8M	-32.15M
YoY Change	193.02%	1621.98%	-7.4%
FREE CASH FLOW
Cash From Operating Activities	-$51.98M	-$70.94M	-$25.30M
Capital Expenditures	-$7.693M	-$3.618M	-$4.481M
Free Cash Flow	-$44.29M	-$67.32M	-$20.82M
YoY Change	548.11%	23.94%	-38.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001818331
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-39482
CY2021	dei	Entity Registrant Name EntityRegistrantName	Sema4 Holdings Corp.
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	85-1966622
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	333 Ludlow Street
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	North Tower, 8th Floor
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Stamford
CY2021	dei	City Area Code CityAreaCode	800
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06902
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	108132000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	26509000	USD
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Local Phone Number LocalPhoneNumber	298-6470
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	515000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	244959781	shares
CY2021	dei	Auditor Firm AuditorFirmId	42
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	New York, New York, United States
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	400569000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	32044000	USD
CY2021Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	54000	USD
CY2020Q4	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	289000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	33456000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	24962000	USD
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	19154000	USD
CY2020Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4557000	USD
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3802000	USD
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	4124000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	483544000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	174108000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62719000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	63110000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10828000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6930000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3596000	USD
CY2021Q4	us-gaap	Assets Assets	554093000	USD
CY2020Q4	us-gaap	Assets Assets	251642000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	44693000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	26737000	USD
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	20108000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	11854000	USD
CY2021Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	2623000	USD
CY2020Q4	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1425000	USD
CY2021Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	3419000	USD
CY2020Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	3506000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	473000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1783000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	29968000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	28137000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	101284000	USD
CY2021Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	18427000	USD
CY2020Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	20778000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	73442000	USD
CY2020Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	131989000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3480000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11000000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	18971000	USD
CY2021Q4	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	0	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2074000	USD
CY2021Q4	cmlf	Warrant Liability WarrantLiability	21555000	USD
CY2020Q4	cmlf	Warrant Liability WarrantLiability	0	USD
CY2021Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	10244000	USD
CY2020Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2021Q4	us-gaap	Liabilities Liabilities	165990000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	247254000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	334439000	USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	963520000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-575441000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-330051000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	554093000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	388103000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-330051000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	251642000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	212195000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	179322000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	196174000	USD
CY2021	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	228797000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	175296000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	113389000	USD
CY2021	us-gaap	Gross Profit GrossProfit	-16602000	USD
CY2020	us-gaap	Gross Profit GrossProfit	4026000	USD
CY2019	us-gaap	Gross Profit GrossProfit	82785000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	105162000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72700000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34910000	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	112738000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	63183000	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	39352000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	205988000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	100742000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29484000	USD
CY2021	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	5659000	USD
CY2020	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	9395000	USD
CY2019	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	9452000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-446149000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-241994000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-30413000	USD
CY2021	cmlf	Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities	198401000	USD
CY2020	cmlf	Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities	0	USD
CY2019	cmlf	Change In Fair Market Value Of Warrant And Earn Out Contingent Liabilities ChangeInFairMarketValueOfWarrantAndEarnOutContingentLiabilities	0	USD
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	79000	USD
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	506000	USD
CY2019	us-gaap	Investment Income Interest InvestmentIncomeInterest	988000	USD
CY2021	us-gaap	Interest Expense InterestExpense	2835000	USD
CY2020	us-gaap	Interest Expense InterestExpense	2474000	USD
CY2019	us-gaap	Interest Expense InterestExpense	783000	USD
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5114000	USD
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2622000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	504000	USD
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	200759000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	654000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	709000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-245390000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-241340000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29704000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-245390000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-245390000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-241340000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-241340000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29704000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-29704000	USD
CY2021	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	0	USD
CY2020	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	0	USD
CY2019	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	3039000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-245390000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-245390000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-241340000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-241340000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32743000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-32743000	USD
CY2018Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	102039134	shares
CY2018Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	64355000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-55968000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-29704000	USD
CY2019	cmlf	Temporary Equity Stock Dividends Shares TemporaryEquityStockDividendsShares	3061173	shares
CY2019	cmlf	Temporary Equity Stock Issued During Period Value Stock Dividend TemporaryEquityStockIssuedDuringPeriodValueStockDividend	3039000	USD
CY2019	us-gaap	Increase In Carrying Amount Of Redeemable Preferred Stock IncreaseInCarryingAmountOfRedeemablePreferredStock	3039000	USD
CY2019	cmlf	Temporary Equity Capital Contribution TemporaryEquityCapitalContribution	30897000	USD
CY2019	cmlf	Temporary Equity Stock Issued During Period Shares New Issues TemporaryEquityStockIssuedDuringPeriodSharesNewIssues	41937960	shares
CY2019	us-gaap	Temporary Equity Stock Issued During Period Value New Issues TemporaryEquityStockIssuedDuringPeriodValueNewIssues	118824000	USD
CY2019Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	147038267	shares
CY2019Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	217115000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-88711000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-241340000	USD
CY2020	us-gaap	Increase In Carrying Amount Of Redeemable Preferred Stock IncreaseInCarryingAmountOfRedeemablePreferredStock	0	USD
CY2020	cmlf	Temporary Equity Capital Contribution Value TemporaryEquityCapitalContributionValue	24496946	shares
CY2020	cmlf	Temporary Equity Capital Contribution TemporaryEquityCapitalContribution	117324000	USD
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	171535213	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	334439000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-330051000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-245390000	USD
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1783000	USD
CY2021	cmlf	Temporary Equity Elimination As Part Of Reorganization Shares TemporaryEquityEliminationAsPartOfReorganizationShares	171535213	shares
CY2021	us-gaap	Temporary Equity Elimination As Partof Reorganization TemporaryEquityEliminationAsPartofReorganization	334439000	USD
CY2021	cmlf	Stock Issued During Period Conversion Of Temporary Equity As Part Of Reorganization StockIssuedDuringPeriodConversionOfTemporaryEquityAsPartOfReorganization	104532000	USD
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	-744000	USD
CY2021	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	510751000	USD
CY2021	cmlf	Share Based Compensation Modification Reclassification ShareBasedCompensationModificationReclassification	304837000	USD
CY2021	cmlf	Stock Based Comp Expense StockBasedCompExpense	42385000	USD
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	388103000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-245390000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-241340000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-29704000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21807000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11734000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6407000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	219421000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	120231000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	5482000	USD
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-198401000	USD
CY2020	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2019	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	2129000	USD
CY2020	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2019	us-gaap	Inventory Write Down InventoryWriteDown	0	USD
CY2021	cmlf	Noncash Lease Expense NoncashLeaseExpense	1555000	USD
CY2020	cmlf	Noncash Lease Expense NoncashLeaseExpense	2400000	USD
CY2019	cmlf	Noncash Lease Expense NoncashLeaseExpense	-176000	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-301000	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	66000	USD
CY2020	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2019	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5535000	USD
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	10611000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4567000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10624000	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8979000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	7970000	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14250000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2498000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2526000	USD
CY2021	cmlf	Increase Decrease In Due To From Related Parties IncreaseDecreaseInDueToFromRelatedParties	1433000	USD
CY2020	cmlf	Increase Decrease In Due To From Related Parties IncreaseDecreaseInDueToFromRelatedParties	-442000	USD
CY2019	cmlf	Increase Decrease In Due To From Related Parties IncreaseDecreaseInDueToFromRelatedParties	-919000	USD
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1861000	USD
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-1175000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4395000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	25916000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14805000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	12847000	USD
CY2021	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1310000	USD
CY2020	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-559000	USD
CY2019	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2342000	USD
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	3239000	USD
CY2020	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	15960000	USD
CY2019	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	4451000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-190434000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-93128000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-18728000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	9400000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24094000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11923000	USD
CY2021	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	11386000	USD
CY2020	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	7880000	USD
CY2019	us-gaap	Payments To Develop Software PaymentsToDevelopSoftware	3533000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20786000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-31974000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-15456000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	350000000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	442684000	USD
CY2020	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	0	USD
CY2019	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	0	USD
CY2021	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	230665000	USD
CY2020	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	0	USD
CY2019	us-gaap	Payments For Repurchase Of Convertible Preferred Stock PaymentsForRepurchaseOfConvertiblePreferredStock	0	USD
CY2021	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	51760000	USD
CY2020	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	0	USD
CY2019	us-gaap	Payments Of Merger Related Costs Financing Activities PaymentsOfMergerRelatedCostsFinancingActivities	0	USD
CY2021	cmlf	Payment For Settlement Of Unvested Stock Appreciation Rights PaymentForSettlementOfUnvestedStockAppreciationRights	3795000	USD
CY2020	cmlf	Payment For Settlement Of Unvested Stock Appreciation Rights PaymentForSettlementOfUnvestedStockAppreciationRights	0	USD
CY2019	cmlf	Payment For Settlement Of Unvested Stock Appreciation Rights PaymentForSettlementOfUnvestedStockAppreciationRights	0	USD
CY2021	us-gaap	Early Repayment Of Senior Debt EarlyRepaymentOfSeniorDebt	8741000	USD
CY2020	us-gaap	Early Repayment Of Senior Debt EarlyRepaymentOfSeniorDebt	0	USD
CY2019	us-gaap	Early Repayment Of Senior Debt EarlyRepaymentOfSeniorDebt	0	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1271000	USD
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2019	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
CY2021	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0	USD
CY2020	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	0	USD
CY2019	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	30897000	USD
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	15928000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2021	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	1000000	USD
CY2020	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	186000	USD
CY2019	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0	USD
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	537000	USD
CY2020	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2019	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	USD
CY2021	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	3728000	USD
CY2020	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	4010000	USD
CY2019	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	1709000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	493729000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	129056000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	148012000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	282509000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	3954000	USD
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	113828000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118960000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115006000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1178000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	401469000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118960000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	115006000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	2751000	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1745000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	305000	USD
CY2021	us-gaap	Income Taxes Paid IncomeTaxesPaid	349000	USD
CY2020	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2019	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	761000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	447000	USD
CY2019	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	818000	USD
CY2021	cmlf	Software Development Costs Incurred But Not Yet Paid SoftwareDevelopmentCostsIncurredButNotYetPaid	1149000	USD
CY2020	cmlf	Software Development Costs Incurred But Not Yet Paid SoftwareDevelopmentCostsIncurredButNotYetPaid	1473000	USD
CY2019	cmlf	Software Development Costs Incurred But Not Yet Paid SoftwareDevelopmentCostsIncurredButNotYetPaid	1040000	USD
CY2021	cmlf	Noncash Redeemable Preferred Stock Dividends NoncashRedeemablePreferredStockDividends	0	USD
CY2020	cmlf	Noncash Redeemable Preferred Stock Dividends NoncashRedeemablePreferredStockDividends	0	USD
CY2019	cmlf	Noncash Redeemable Preferred Stock Dividends NoncashRedeemablePreferredStockDividends	3039000	USD
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1000000	USD
CY2020	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2019	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0	USD
CY2021	us-gaap	Nature Of Operations NatureOfOperations	Organization and Description of Business <div style="margin-bottom:9pt;margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sema4 Holdings Corp., formerly Mount Sinai Genomics Inc., a Delaware corporation (“Legacy Sema4”), as discussed further below, provides genomics-related diagnostic and information services and pursues genomics medical research. Legacy Sema4 utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process DNA-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. Legacy Sema4 provides a variety of genetic diagnostic tests and information with a focus on reproductive health, including pediatric, oncology and other conditions. In 2020, the Legacy Sema4 began to provide diagnostic testing services in response to the outbreak of the coronavirus (“COVID-19”) pandemic. On December 15, 2021, it was announced that COVID-19 testing services would be discontinued by March 31, 2022. Legacy Sema4 primarily serves healthcare professionals who work with their patients and bills third-party payors across the United States, with a substantial portion of its diagnostic testing volume occurring in New York, California, Florida, Connecticut and New Jersey. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2021 (the “Closing Date”), CM Life Sciences, Inc. (“CMLS”) completed the acquisition of Legacy Sema4, pursuant to that certain Agreement and Plan of Merger (as amended, the “Merger Agreement”), dated February 9, 2021. On the Closing Date, S-IV Sub, Inc. (“Merger Sub”) merged with and into the Legacy Sema4, with Legacy Sema4 surviving the merger as a wholly-owned subsidiary of CMLS (the “Merger” and, together with the other transactions contemplated by the Merger Agreement, the “Business Combination”). In connection with the consummation of the Business Combination, CMLS changed its name to “Sema4 Holdings Corp.” (“Sema4 Holdings”) and Legacy Sema4 changed its name to “Sema4 OpCo, Inc.” All equity securities of Legacy Sema4 were converted into the right to receive the applicable portion of the merger consideration.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Merger was accounted for as a reverse recapitalization with Legacy Sema4 as the accounting acquirer and CMLS as the acquired company for accounting purposes. The shares and net loss per common share, prior to the Merger, have been retroactively restated as shares reflecting the exchange ratio established in the Merger (1 share of Legacy Sema4 Class A common stock for 123.8339 shares of Sema4 Holdings Class A common stock) (the “Conversion Ratio”).</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the Merger, shares of CMLS Class A common stock, CMLS’s public warrants, and CMLS’s public units were traded on the Nasdaq Capital Market under the ticker symbols “CMLF”, “CMFLW”, and “CMLFU” respectively. On July 23, 2021, shares of Sema4 Holdings Class A common stock and Sema4 Holdings’ public warrants began trading on the Nasdaq Global Select Market (the “Nasdaq”) under the ticker symbols “SMFR” and “SMFRW,” respectively. See Note 3, “Business Combination,” for additional details.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated herein or unless the context otherwise requires, references in these notes to the “Company,” or “Sema4” refer to (i) Legacy Sema4 prior to the consummation of the Business Combination; and (ii) Sema4 Holdings and its subsidiary following the consummation of the Business Combination.</span></div>
CY2021	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	Restatement – 2020 and 2019 annual statements of operations and comprehensive lossThe Company classifies expenses incurred that directly relate to the delivery of revenue as cost of services in its consolidated statements of operations and comprehensive loss.
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	179322000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	196174000	USD
CY2020	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	175296000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	113389000	USD
CY2020	us-gaap	Gross Profit GrossProfit	4026000	USD
CY2019	us-gaap	Gross Profit GrossProfit	82785000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72700000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	34910000	USD
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	63183000	USD
CY2019	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	39352000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	100742000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	29484000	USD
CY2020	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	9395000	USD
CY2019	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	9452000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-241994000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	-30413000	USD
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	654000	USD
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	709000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-241340000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-241340000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29704000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	-29704000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	64201000	USD
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	47015000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	68524000	USD
CY2021Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	48179000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	-4323000	USD
CY2021Q2	us-gaap	Gross Profit GrossProfit	-1164000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	53133000	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11952000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	35366000	USD
CY2021Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	18574000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	102038000	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12870000	USD
CY2021Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	1797000	USD
CY2021Q2	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	888000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-196657000	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-45448000	USD
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4882000	USD
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-713000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-191775000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-191775000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-46161000	USD
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-46161000	USD
CY2021Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	43178000	USD
CY2021Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	57801000	USD
CY2021Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	51487000	USD
CY2021Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	60607000	USD
CY2021Q3	us-gaap	Gross Profit GrossProfit	-8309000	USD
CY2021Q4	us-gaap	Gross Profit GrossProfit	-2806000	USD
CY2021Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17831000	USD
CY2021Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	22246000	USD
CY2021Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	28152000	USD
CY2021Q4	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	30646000	USD
CY2021Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33125000	USD
CY2021Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	57955000	USD
CY2021Q3	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	847000	USD
CY2021Q4	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	2127000	USD
CY2021Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-88264000	USD
CY2021Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-115780000	USD
CY2021Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	120995000	USD
CY2021Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	75595000	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	32731000	USD
CY2021Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	32731000	USD
CY2021Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-40185000	USD
CY2021Q4	us-gaap	Net Income Loss NetIncomeLoss	-40185000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	46655000	USD
CY2020Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	30102000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	38608000	USD
CY2020Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	63957000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	37138000	USD
CY2020Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	34505000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	34022000	USD
CY2020Q4	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	69631000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	9517000	USD
CY2020Q2	us-gaap	Gross Profit GrossProfit	-4403000	USD
CY2020Q3	us-gaap	Gross Profit GrossProfit	4586000	USD
CY2020Q4	us-gaap	Gross Profit GrossProfit	-5674000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13096000	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9361000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	19083000	USD
CY2020Q4	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	31160000	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	13834000	USD
CY2020Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	10166000	USD
CY2020Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	15243000	USD
CY2020Q4	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	23940000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7164000	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8121000	USD
CY2020Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	24342000	USD
CY2020Q4	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	61115000	USD
CY2020Q1	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	2195000	USD
CY2020Q2	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	2111000	USD
CY2020Q3	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	1933000	USD
CY2020Q4	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	3156000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-26772000	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-34162000	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-56015000	USD
CY2020Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-125045000	USD
CY2020Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-218000	USD
CY2020Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2110000	USD
CY2020Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-600000	USD
CY2020Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-638000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-26990000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-26990000	USD
CY2020Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32052000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-32052000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-56615000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-56615000	USD
CY2020Q4	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-125683000	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-125683000	USD
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58652000	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26501000	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	461276000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	33340000	USD
CY2021Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	24568000	USD
CY2021Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	21257000	USD
CY2021Q1	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	349000	USD
CY2021Q2	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	437000	USD
CY2021Q3	us-gaap	Due From Related Parties Current DueFromRelatedPartiesCurrent	413000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	32969000	USD
CY2021Q2	us-gaap	Inventory Net InventoryNet	29128000	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	31174000	USD
CY2021Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	14931000	USD
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	18378000	USD
CY2021Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	24391000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	140241000	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	99012000	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	538511000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	64632000	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62097000	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	60333000	USD
CY2021Q1	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10828000	USD
CY2021Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10828000	USD
CY2021Q3	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3596000	USD
CY2021Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3596000	USD
CY2021Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	3613000	USD
CY2021Q1	us-gaap	Assets Assets	219297000	USD
CY2021Q2	us-gaap	Assets Assets	175533000	USD
CY2021Q3	us-gaap	Assets Assets	603357000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	42102000	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	45231000	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	43321000	USD
CY2021Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	797000	USD
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1278000	USD
CY2021Q3	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	1425000	USD
CY2021Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	2810000	USD
CY2021Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1341000	USD
CY2021Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	493000	USD
CY2021Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	22991000	USD
CY2021Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	24764000	USD
CY2021Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	26369000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	68700000	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	72614000	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	71608000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	18502000	USD
CY2021Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	18028000	USD
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11000000	USD
CY2021Q1	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	296952000	USD
CY2021Q2	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	295049000	USD
CY2021Q3	us-gaap	Deferred Compensation Liability Classified Noncurrent DeferredCompensationLiabilityClassifiedNoncurrent	0	USD
CY2021Q1	cmlf	Warrant Liability WarrantLiability	0	USD
CY2021Q2	cmlf	Warrant Liability WarrantLiability	0	USD
CY2021Q3	cmlf	Warrant Liability WarrantLiability	46629000	USD
CY2021Q1	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2021Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	0	USD
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	61400000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	22530000	USD
CY2021Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21907000	USD
CY2021Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	21699000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	406684000	USD
CY2021Q2	us-gaap	Liabilities Liabilities	407598000	USD
CY2021Q3	us-gaap	Liabilities Liabilities	212336000	USD
CY2021Q3	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21995000	shares
CY2021Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	334439000	USD
CY2021Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	334439000	USD
CY2021Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0	USD
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	0	USD
CY2021Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1483000	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	926253000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-521826000	USD
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-567987000	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-535256000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-521826000	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	-566504000	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	391021000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	219297000	USD
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	21994972	shares
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	175533000	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	603357000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;margin-top:10pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements requires management to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and the related disclosures at the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. The Company bases these estimates on current facts, historical and anticipated results, trends and various other assumptions that it believes are reasonable in the circumstances, including assumptions as to future events. These estimates include, but are not limited to, the transaction price for certain contracts with customers, the capitalization of software costs and the valuation of stock-based awards, inventory, earn-out contingent liability and earn-out RSUs. Actual results could differ materially from those estimates, judgments and assumptions.</span></div>
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s cash and cash equivalents are deposited with high-quality financial institutions. The Company has balances in financial institutions that exceed federal depository insurance limits. Management believes these financial institutions are financially sound and, accordingly, that minimal credit risk exists. The Company has not experienced any losses on its deposits of cash and cash equivalents. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses both the customer and, if applicable, the third party payor that reimburses the Company on the customer’s behalf when evaluating concentration of credit risk. Significant customers and payors are those that represent more than 10% of the Company’s total annual revenues or accounts receivable balance at each respective balance sheet date. The significant concentrations of accounts receivable as of December 31, 2021 and 2020 were primarily from large managed care insurance companies and a reference laboratory. There was no individual customer that accounted for 10% or more of revenue or accounts receivable for any of the years presented. The Company does not require collateral as a means to mitigate customer credit risk.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For each significant payor, revenue as a percentage of total revenues and accounts receivable as a percentage of total accounts receivable are as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.303%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.761%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.845%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accounts Receivable</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor A</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor B</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor C</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payor D</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"></span></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">less than 10%</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a concentration of risk from a limited number of suppliers for certain reagents and laboratory supplies. One supplier accounted for approximately 7%, 11% and 15% for the years ended December 31, 2021, 2020 and 2019, respectively. Another supplier accounted for approximately 11%, 10% and 12% for the years ended December 31, 2021, 2020 and 2019, respectively. This risk is managed by maintaining a target quantity of surplus stock.</span></div>
CY2020	cmlf	Proceeds From Government Assistance ProceedsFromGovernmentAssistance	5400000	USD
CY2020Q4	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	3800000	USD
CY2021Q4	cmlf	Payment Of Deferred Payroll Taxes PaymentOfDeferredPayrollTaxes	1900000	USD
CY2021Q4	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	1900000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	400569000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	108132000	USD
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	900000	USD
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	10828000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	401469000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118960000	USD
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	200000	USD
CY2021Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	2100000	USD
CY2020Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	0	USD
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2019	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021Q4	cmlf	Warrants To Purchase Public Warrants WarrantsToPurchasePublicWarrants	14758305	shares
CY2021Q4	cmlf	Class Of Warrant Or Right Target Share Price Of Warrants Or Rights For Redemption ClassOfWarrantOrRightTargetSharePriceOfWarrantsOrRightsForRedemption	18.00
CY2021	cmlf	Redemption Price Per Warrant RedemptionPricePerWarrant	0.01
CY2021	cmlf	Number Of Days For Written Notice Of Redemption NumberOfDaysForWrittenNoticeOfRedemption	30	D
CY2021	cmlf	Common Stock Threshold Trading Days CommonStockThresholdTradingDays	30	D
CY2021	cmlf	Revenue Recognition Standard Payment Term RevenueRecognitionStandardPaymentTerm	P60D
CY2021	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021	us-gaap	Hosting Arrangement Service Contract Implementation Cost Impairment HostingArrangementServiceContractImplementationCostImpairment	2300000	USD
CY2021	us-gaap	Hosting Arrangement Service Contract Implementation Cost Impairment HostingArrangementServiceContractImplementationCostImpairment	2300000	USD
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	212195000	USD
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	179322000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	196174000	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	10200000	USD
CY2021Q4	us-gaap	Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1	P3Y3M18D
CY2020Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	2028000	USD
CY2020Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3811000	USD
CY2021	cmlf	Contract With Customer Asset Additions ContractWithCustomerAssetAdditions	1163000	USD
CY2021	cmlf	Contract With Customer Liability Additions ContractWithCustomerLiabilityAdditions	0	USD
CY2021	us-gaap	Contract With Customer Asset Reclassified To Receivable ContractWithCustomerAssetReclassifiedToReceivable	0	USD
CY2021	cmlf	Contract With Customer Liability Prepayments ContractWithCustomerLiabilityPrepayments	2223000	USD
CY2021	cmlf	Contract With Customer Asset Revenue Recognized ContractWithCustomerAssetRevenueRecognized	105000	USD
CY2021	cmlf	Contract With Customer Liability Revenue Recognized Including Opening Balance ContractWithCustomerLiabilityRevenueRecognizedIncludingOpeningBalance	2265000	USD
CY2021Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	3296000	USD
CY2021Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	3769000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	500000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	500000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1800000	USD
CY2020Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	1800000	USD
CY2021Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	1800000	USD
CY2021Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	1800000	USD
CY2020Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	3000000	USD
CY2020Q4	us-gaap	Capitalized Contract Cost Net CapitalizedContractCostNet	3000000	USD
CY2021Q4	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	1400000	USD
CY2020Q4	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	900000	USD
CY2019Q4	us-gaap	Capitalized Contract Cost Net Current CapitalizedContractCostNetCurrent	700000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	400600000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	114625000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	93209000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	51906000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	30099000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	62719000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	63110000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21800000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11700000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6400000	USD
CY2021	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	5600000	USD
CY2020	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	3000000	USD
CY2019	us-gaap	Capitalized Computer Software Amortization1 CapitalizedComputerSoftwareAmortization1	1200000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21807000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	11734000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6407000	USD
CY2017Q2	cmlf	Related Party Transaction Funding Commitment To Be Received Maximum RelatedPartyTransactionFundingCommitmentToBeReceivedMaximum	55000000	USD
CY2019Q4	cmlf	Cumulative Funding CumulativeFunding	55000000	USD
CY2021	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	1300000	USD
CY2021Q4	us-gaap	Due To Related Parties Current And Noncurrent DueToRelatedPartiesCurrentAndNoncurrent	100000	USD
CY2021Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.0400
CY2021Q4	us-gaap	Line Of Credit LineOfCredit	0	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	875000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	2131000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	2174000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	2218000	USD
CY2021Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	3602000	USD
CY2021Q4	us-gaap	Long Term Debt LongTermDebt	11000000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11000000	USD
CY2019Q2	cmlf	Lease Obligation Term LeaseObligationTerm	P325M
CY2019Q2	cmlf	Lease Cancellation Period LeaseCancellationPeriod	P196M
CY2019Q2	us-gaap	Retail Land Sales Receivables Stated Interest Rate RetailLandSalesReceivablesStatedInterestRate	0.25
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	4383000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4474000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4562000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4684000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	4775000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	45463000	USD
CY2021Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	68341000	USD
CY2021	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	5700000	USD
CY2020	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	5300000	USD
CY2019	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	800000	USD
CY2021	cmlf	Month To Month Operating Lease Rent Expense MonthToMonthOperatingLeaseRentExpense	1200000	USD
CY2020	cmlf	Month To Month Operating Lease Rent Expense MonthToMonthOperatingLeaseRentExpense	3200000	USD
CY2019	cmlf	Month To Month Operating Lease Rent Expense MonthToMonthOperatingLeaseRentExpense	2800000	USD
CY2021Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	27700000	USD
CY2021Q4	cmlf	Capital Lease Interest Rate Stated Percentage CapitalLeaseInterestRateStatedPercentage	0.131
CY2020Q4	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	27000000	USD
CY2021Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	13600000	USD
CY2020Q4	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	9700000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	4890000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	3584000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	2763000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Four Years CapitalLeasesFutureMinimumPaymentsDueInFourYears	2451000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due In Five Years CapitalLeasesFutureMinimumPaymentsDueInFiveYears	2003000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due Thereafter CapitalLeasesFutureMinimumPaymentsDueThereafter	49883000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	65574000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	43728000	USD
CY2021Q4	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	21846000	USD
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	4000000	USD
CY2021Q4	us-gaap	Capital Lease Obligations Current CapitalLeaseObligationsCurrent	3419000	USD
CY2021Q4	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	18427000	USD
CY2021Q4	cmlf	Assets Acquired Under Capital Leases AssetsAcquiredUnderCapitalLeases	600000	USD
CY2020Q4	cmlf	Assets Acquired Under Capital Leases AssetsAcquiredUnderCapitalLeases	7500000	USD
CY2019Q4	cmlf	Assets Acquired Under Capital Leases AssetsAcquiredUnderCapitalLeases	9800000	USD
CY2021	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	2300000	USD
CY2020	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	2200000	USD
CY2019	us-gaap	Interest Expense Lessee Assets Under Capital Lease InterestExpenseLesseeAssetsUnderCapitalLease	700000	USD
CY2021Q4	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	16647000	USD
CY2021Q4	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	5165000	USD
CY2021Q4	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	1279000	USD
CY2021Q4	us-gaap	Purchase Obligation PurchaseObligation	23091000	USD
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	8000000	USD
CY2020	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	5500000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	400000	USD
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y9M25D
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	159899000	USD
CY2021Q4	cmlf	Share Based Compensation Arrangement By Share Based Payment Award Options Number Of Shares Available For Grant Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNumberOfSharesAvailableForGrantOutstanding	30905543	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.24
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	109887000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y29D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	92974000	USD
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	7975234	shares
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	8.38
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.97
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	44600000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue	10.52
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	17100000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	600000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0.0	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Based Liabilities Paid ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid	100000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Based Liabilities Paid ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid	300000	USD
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Based Liabilities Paid ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareBasedLiabilitiesPaid	1000000.0	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6580
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.6000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.6615
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.6580
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.6000
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0010
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	9900000	USD
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions	3500000	USD
CY2021	cmlf	Share Based Payment Arrangement Number Of Individuals Granted ShareBasedPaymentArrangementNumberOfIndividualsGranted	1	employee
CY2021	cmlf	Share Based Payment Arrangement Number Of Individuals Granted ShareBasedPaymentArrangementNumberOfIndividualsGranted	1	consultant
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	219421000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	120231000	USD
CY2019	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5482000	USD
CY2021Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	0	shares
CY2020Q4	us-gaap	Temporary Equity Shares Authorized TemporaryEquitySharesAuthorized	186554160	shares
CY2020Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	171535213	shares
CY2020Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	171535213	shares
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	334439000	USD
CY2020Q4	us-gaap	Temporary Equity Liquidation Preference TemporaryEquityLiquidationPreference	430041000	USD
CY2021Q3	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	230000000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	0	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-245390000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-241340000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-29704000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-245390000	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-241340000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29704000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.105
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.021
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.035
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.007
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.006
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.034
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.113
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.078
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.033
CY2021	cmlf	Effective Income Tax Rate Reconciliation Nondeductible Expense Pay For Covered Employees Limitation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpensePayForCoveredEmployeesLimitationPercent	0.057
CY2020	cmlf	Effective Income Tax Rate Reconciliation Nondeductible Expense Pay For Covered Employees Limitation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpensePayForCoveredEmployeesLimitationPercent	0
CY2019	cmlf	Effective Income Tax Rate Reconciliation Nondeductible Expense Pay For Covered Employees Limitation Percent EffectiveIncomeTaxRateReconciliationNondeductibleExpensePayForCoveredEmployeesLimitationPercent	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.002
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.005
CY2021	cmlf	Effective Income Tax Rate Reconciliation Unrealized Fair Market Value Gain On Warrants EffectiveIncomeTaxRateReconciliationUnrealizedFairMarketValueGainOnWarrants	0.170
CY2020	cmlf	Effective Income Tax Rate Reconciliation Unrealized Fair Market Value Gain On Warrants EffectiveIncomeTaxRateReconciliationUnrealizedFairMarketValueGainOnWarrants	0
CY2019	cmlf	Effective Income Tax Rate Reconciliation Unrealized Fair Market Value Gain On Warrants EffectiveIncomeTaxRateReconciliationUnrealizedFairMarketValueGainOnWarrants	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.320
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.159
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.241
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	132075000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	44583000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	12311000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	7538000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	4170000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	2337000	USD
CY2021Q4	cmlf	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Transaction Costs DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTransactionCosts	416000	USD
CY2020Q4	cmlf	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Transaction Costs DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsTransactionCosts	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7285000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	4667000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	1443000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent	493000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	145000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	186000	USD
CY2021Q4	cmlf	Deferred Tax Assets Tax Deferred Expense Employer Taxes DeferredTaxAssetsTaxDeferredExpenseEmployerTaxes	932000	USD
CY2020Q4	cmlf	Deferred Tax Assets Tax Deferred Expense Employer Taxes DeferredTaxAssetsTaxDeferredExpenseEmployerTaxes	1050000	USD
CY2021Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	372000	USD
CY2020Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	479000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	608000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	655000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	51000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	23000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	160463000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	61356000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	155668000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	58264000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4795000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	3092000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	685000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Other Finite Lived Assets DeferredTaxLiabilitiesOtherFiniteLivedAssets	4795000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Other Finite Lived Assets DeferredTaxLiabilitiesOtherFiniteLivedAssets	2407000	USD
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4795000	USD
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	3092000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	97400000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	38100000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7100000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	537000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	374000	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	195000	USD
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	163000	USD
CY2019	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	179000	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	537000	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	537000	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	374000	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-245390000	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-241340000	USD
CY2019	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32743000	USD
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	108077439	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	108077439	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5131	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5131	shares
CY2019	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	124	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	124	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.27
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.27
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-47036
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-47036
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-264056
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-264056
CY2021	cmlf	Conversion Ratio ConversionRatio	123.8339
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	76536415	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	189958359	shares
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	143790282	shares
CY2021Q4	cmlf	Accrued Bonus Current AccruedBonusCurrent	13561000	USD
CY2020Q4	cmlf	Accrued Bonus Current AccruedBonusCurrent	9821000	USD
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7013000	USD
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6834000	USD
CY2021Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	1057000	USD
CY2020Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	3663000	USD
CY2021Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	2826000	USD
CY2020Q4	us-gaap	Accrued Sales Commission Current AccruedSalesCommissionCurrent	1540000	USD
CY2021Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1770000	USD
CY2021Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	5511000	USD
CY2020Q4	us-gaap	Other Sundry Liabilities Current OtherSundryLiabilitiesCurrent	4509000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	29968000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	28137000	USD

Files In Submission

Name	View Source	Status
0001818331-22-000037-index-headers.html	Edgar Link	pending
0001818331-22-000037-index.html	Edgar Link	pending
0001818331-22-000037.txt	Edgar Link	pending
0001818331-22-000037-xbrl.zip	Edgar Link	pending
a10-kxeyconsent.htm	Edgar Link	pending
ceocertificationfor-ex311x.htm	Edgar Link	pending
ceocertificationfor-ex321x.htm	Edgar Link	pending
cfocertificationfor-ex312x.htm	Edgar Link	pending
cfocertificationfor-ex322x.htm	Edgar Link	pending
cmlf-20211231.htm	Edgar Link	pending
cmlf-20211231.xsd	Edgar Link	pending
cmlf-20211231_cal.xml	Edgar Link	unprocessable
cmlf-20211231_def.xml	Edgar Link	unprocessable
cmlf-20211231_g1.jpg	Edgar Link	pending
cmlf-20211231_htm.xml	Edgar Link	completed
cmlf-20211231_lab.xml	Edgar Link	unprocessable
cmlf-20211231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
fw_15470948x3xsema4-execut.htm	Edgar Link	pending
image_0.jpg	Edgar Link	pending
image_2.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
sema4-10xkfy2021xex211subs.htm	Edgar Link	pending
sema4-descriptionofsecurit.htm	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$WGS
GeneDx Holdings Corp. Stock $wgs

2021 Q4 Form 10-K Financial Statement

#000181833122000037 Filed on March 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WGS GeneDx Holdings Corp. Stock $wgs

2021 Q4 Form 10-K Financial Statement

#000181833122000037 Filed on March 14, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$WGS
GeneDx Holdings Corp. Stock $wgs